Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia.
about
Year in review 2013: Critical Care--respiratory infectionsTreatment of Gram-positive infections in critically ill patientsCurrent and Future Considerations for the Treatment of Hospital-Acquired PneumoniaAntibiotic stewardship in the intensive care unit.Predictive Factors of Methicillin-Resistant Staphylococcus aureus Infection in Elderly Patients with Community-Onset Pneumonia.Epidemiology and predictors of multidrug-resistant community-acquired and health care-associated pneumonia.A comparison of microbiology and demographics among patients with healthcare-associated, hospital-acquired, and ventilator-associated pneumonia: a retrospective analysis of 1184 patients from a large, international studyStaphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.Clinical implications for patients treated inappropriately for community-acquired pneumonia in the emergency department.Update in sepsis and pulmonary infections 2013.The burden and etiology of community-onset pneumonia in the aging Japanese population: a multicenter prospective study.Molecular epidemiological characteristics of Klebsiella pneumoniae associated with bacteremia among patients with pneumonia.Individualizing risk of multidrug-resistant pathogens in community-onset pneumonia.Bacteriological assessment of healthcare-associated pneumonia using a clone library analysisAn international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance.Comparison of clinical prediction models for resistant bacteria in community-onset pneumonia.Mechanisms of antimicrobial resistance in Gram-negative bacilli.A mortality prediction rule for non-elderly patients with community-acquired pneumoniaThe significance of oral streptococci in patients with pneumonia with risk factors for aspiration: the bacterial floral analysis of 16S ribosomal RNA gene using bronchoalveolar lavage fluidTrends in Antibiotic Use and Nosocomial Pathogens in Hospitalized Veterans With Pneumonia at 128 Medical Centers, 2006-2010.Derivation and Multicenter Validation of the Drug Resistance in Pneumonia Clinical Prediction Score.A cohort study of bacteremic pneumonia: The importance of antibiotic resistance and appropriate initial therapy?Relation between presence of extended-spectrum β-lactamase-producing Enterobacteriaceae in systematic rectal swabs and respiratory tract specimens in ICU patients.Are third-generation cephalosporins unavoidable for empirical therapy of community-acquired pneumonia in adult patients who require ICU admission? A retrospective studyThe bacterial pneumonias: a new treatment paradigm.Regional differences in antibiotic-resistant pathogens in patients with pneumonia: Implications for clinicians.The respiratory threat posed by multidrug resistant Gram-negative bacteria.Variation in Empiric Coverage Versus Detection of Methicillin-Resistant Staphylococcus aureus and Pseudomonas aeruginosa in Hospitalizations for Community-Onset Pneumonia Across 128 US Veterans Affairs Medical Centers.Sepsis: Current Definition, Pathophysiology, Diagnosis, and Management.Health care-associated pneumonia in the intensive care unit: Guideline-concordant antibiotics and outcomes.Clinical predictors of methicillin-resistant Staphylococcus aureus in nosocomial and healthcare-associated pneumonia: a multicenter, matched case-control study.Impact of Combination Antibiogram and Related Education on Inpatient Fluoroquinolone Prescribing Patterns for Patients With Health Care-Associated Pneumonia.The First Case of Pseudomonas aeruginosa Bacteremic Pneumonia in a Cancer Patient Receiving Pegfilgrastim.Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia.Predictors of Pseudomonas and methicillin-resistant Staphylococcus aureus in hospitalized patients with healthcare-associated pneumonia.Interleukin 7 immunotherapy improves host immunity and survival in a two-hit model of Pseudomonas aeruginosa pneumonia.Staphylococcus aureus Community-acquired Pneumonia: Prevalence, Clinical Characteristics, and Outcomes.Pseudomonas aeruginosa nosocomial pneumonia: impact of pneumonia classification.Risk factors for multidrug-resistant pathogens in bronchiectasis exacerbations.Healthcare-associated pneumonia: a never-ending story.
P2860
Q27003346-9C4AD3E4-B720-4B6C-B0ED-C9F8C068206EQ27015976-84B720B8-2EF7-415D-AE5B-343E3FF0F120Q28071882-BADB7F46-CEA3-4CE5-9C4C-91423CBDAF05Q30408712-CB60695D-ACE1-4937-AE08-6A99EE16ADEFQ33567395-90AAD8E3-8B04-452D-AE64-BF7F85F54605Q34057602-FD92C61E-7262-4052-9C0E-1C1BFA32A365Q34464399-2F9E2A8A-3DAF-4336-A2BD-CDACB48785C2Q34478074-92372E8E-F012-4E29-913A-9C6A00F3D9FAQ35086947-0826A0A2-A050-45C3-A500-97B5B6FF6967Q35199001-C8E5E221-996D-4746-BC9D-ABBB1E8595F1Q35231034-D0446B4E-3F34-4C8F-BFC4-AE6E859F27A8Q35331017-BEB9770E-8351-472F-99FC-2DCF6A162C2EQ35362847-A2E614A2-0E9E-464D-B636-ABA1AD6FE566Q35432136-455CB357-2C41-471A-AB3E-4AB2FA2008AAQ35658881-D1E1A69C-F3C0-40B3-834A-97E26582CAF4Q35732814-89BDD752-426F-4C02-B752-6EC7FE13009DQ35935319-B2BF9F22-4BFD-4A60-BAEE-302AB1C04653Q35949943-721FD248-E735-41E6-B755-6C7AC12473E2Q36015030-CD6AE68A-5C5C-4F49-BF24-89256567578CQ36141276-A1C5849E-8879-4AEB-8D5D-EC62401C694CQ36888089-EB08B8F9-41C6-421E-A68B-AFD9C64426F2Q37226357-56180C77-859A-4BC2-8CCE-029EC29D9019Q37622014-3409C5E2-486C-41F3-9D1C-7C9F9E84DF78Q37721755-C2D5709F-61AE-49BD-86DD-D4EC783902BDQ38307688-CA9003D6-289C-449E-B60A-A3577201C2B7Q38646554-F2E45BC3-AFE9-4571-8EB9-199EEC0BC49EQ38662137-04C4A806-650D-451E-A31C-2033A13D29E7Q38716765-8265CAB8-7E06-4C95-85B8-E2F078BBD85AQ39326078-BE5BCFEB-B3D3-4B7C-B509-B249A73A69FEQ39422204-DD14E00D-6A64-4DF3-BBAF-5718A4635F95Q40059530-B011F35C-9834-4208-BFF5-2614DC4899C3Q40090523-C6EC9206-BD19-436F-93A7-DB2421F36176Q40109292-E269F82C-3586-4D53-893D-072318AC6FAEQ40177316-27565D46-F8DC-40FF-BD83-29A24569348EQ40196287-C8EE8AA4-E719-45EC-B628-E3E7DFBE9BF4Q40539825-AF13EB28-62E2-4BE4-867F-6CF9B0908B23Q40681222-E7BDB3F8-B4F1-4CDD-A940-2563591CB250Q41100567-3B783809-AC72-4E8B-B76C-08CCEE4190F3Q41992671-689045EF-F29F-4738-A0C0-7975CE050254Q42060365-3C9A1BCB-4392-409B-8F58-418A91C63A1F
P2860
Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Risk factors for drug-resistan ...... althcare-associated pneumonia.
@en
Risk factors for drug-resistan ...... althcare-associated pneumonia.
@nl
type
label
Risk factors for drug-resistan ...... althcare-associated pneumonia.
@en
Risk factors for drug-resistan ...... althcare-associated pneumonia.
@nl
prefLabel
Risk factors for drug-resistan ...... althcare-associated pneumonia.
@en
Risk factors for drug-resistan ...... althcare-associated pneumonia.
@nl
P2093
P2860
P1476
Risk factors for drug-resistan ...... althcare-associated pneumonia.
@en
P2093
Akira Shiraki
Daisuke Kobayashi
Fumio Nomura
Hideo Saka
Hiroshi Saito
Hiroyuki Taniguchi
Ikuo Yamaguchi
Joe Shindoh
Junya Okumura
P2860
P304
P356
10.1164/RCCM.201301-0079OC
P407
P577
2013-10-01T00:00:00Z